Human parvovirus B19: A review

Acta Virologica

Volumn 58, Issue 3, 2014, Pages 199-213

  Rogo, L D ^a,b   Mokhtari Azad, T ^b   Kabir, M H ^b,c   Rezaei, F ^b  

^a BAYERO UNIVERSITY   (Nigeria)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c USMANU DANFODIYO UNIVERSITY   (Nigeria)

Author keywords

Anemia; Biology; Fifth disease; Genome; Human parvovirus B19; Respiratory pathogen; Transient aplastic crisis

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; DNA ANTIBODY; EPITOPE; GLOBOSIDE; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; PARVOVIRUS VACCINE; PROTEIN VP2; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VIRUS VACCINE;

ANTIVIRAL THERAPY; APOPTOSIS; BONE MARROW; CELL CULTURE; CELL DEATH; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL FEATURE; DRUG SAFETY; FUNCTIONAL GENOMICS; GENOME ANALYSIS; HAND WASHING; HETEROLOGOUS EXPRESSION; HOST SUSCEPTIBILITY; HUMAN; HUMAN PARVOVIRUS B19; IMMUNE RESPONSE; IMMUNOGENICITY; IN SITU HYBRIDIZATION; IN VITRO STUDY; INTERNALIZATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; OPEN READING FRAME; PARVOVIRUS INFECTION; PATHOGENESIS; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; REVIEW; SEROPREVALENCE; TRANSACTIVATION; VIRUS CELL INTERACTION; VIRUS DIAGNOSIS; VIRUS LIKE AGENT; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; GENETICS; PARVOVIRIDAE INFECTIONS; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN;

EID: 84924842441     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2014_03_199     Document Type: Review

References (148)

1. Aberham C, Pendl C, Gross P, Zerlauth G, Gessner M (2001): A quantitative, internally controlled real-time PCR Assay for the detection of parvovirus B19 DNA. J. Virol. Methods 92, 183-191. http://dx.doi.Org/l 0.1016/SO166- 0934(00)00292-5
2. Agbandje M, Kajigaya S, MoKenna R, Young NS, Rossmann MG (1994): The structure of human parvovirus B19 at 8 A resolution. Virology 203, 106-115. http://dx.doi.org/10.1006/viro. 1994.1460
3. Agbandje M, McKenna R, Rossmann MG, Kajigaya S, Young NS (1991): Preliminary X-ray crystallographic investigation of human parvovirus B19. Virology 184,170-174. hltp://dx.doi.org/10.1016/0042-6822(91)90833-W
4. Aktepe OC, Yetgin S, Olcay L, Ozbek N (2004): Human parvovirus B19 associated with idiopathic thrombocytopenic purpura. Pediatr. Hematol. Oncol. 21, 421-426. hup:// dx.doi.org/10.1080/08880010490457141
5. Anderson LJ (1987): Role of parvovirus B19 in human disease. Pediatr. Infect. Dis. J. 6, 711-718. http://dx.doi.org/10.1097/00006454-198708000-00003
6. Anderson LJ, Tsou C, Parker RA (1986): Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 24, 522-526.
7. Anderson MJ, liggins PG, Davis LR, Willman JS, Jones SE, Kidd 1M, PattisonJR,Tyrrell DA(1985): Experimental parvoviral infection in humans. J. Infect. Dis. 152, 257-265. http://dx.doi.Org/IQ.1093/infdis/152.2.257
8. Arend WP, Dayer JM (1990): Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 33, 305-315. http://dx.doi.org/10.1002/art.l780330302
9. Azzi A, Morfini M, Mannucci PM (1999): The transfusionassociated transmission of parvovirus B19. Transfus. Med. Rev. 13,194-204. http://dx.doi.orp/10.1016/S0887- 7963(99)80033-9
10. Barah F, Vallely PJ, Cleator GM, Kerr JR. (2003): Neurological manifestations of human parvovirus B19 infection. Rev. Med. Virol. 13, 185-199. http://dx.doi.org/10.1002/nTiv.388
11. Barsoum NR, Bunnapradist S, Mougdil A, Toyoda M, Vo A, Jordan SC (2002): Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence. Am. J. Transplant. 2, 425-428. http://dx.doi.Org/10.1034/i.1600-6143.2002.20505.x
12. Bay I is SA, Ma L, Padley DJ, Heath AB Yu M W (2012): Collaborative study to establish a World Health Organization International genotype panel for parvovirus B19 DNA nucleic acid amplification technology (NAT)-based assays. Vox Sang 102, 204-211. http://dx.doi.org/IO.1111/i.1423- 0410.2011.01541.x
13. Bertoni E, Rosati A, Zanazzi M, Azzi A, Zakrzewska K., Guidi S, Fanci R, Salvadori M (1997): Aplastic anemia due to B19 parvovirus infection in cadaveric renal transplant recipients: An underestimated infectious disease in the immunocompromised host. J. Nephrol. 10, 152-156.
14. Bock CT (2006): Parvovirus B19: A new emerging pathogenic agent of inflammatory cardiomyopathy. Ernst Schering Research Found Workshop, pp. 83-97.
15. Bonvicini F, Filippone C, Manaresi E (2006): Peptide nucleic acid-based in situ hybridization assay for detection of parvovirus B19 nucleic acids. Clin. Chem. 52,973-978. http://dx.doi.org/IO.1373/clinchem.2005.064741
16. Bonvicini F, Mirasoli M, Gallinella G, Zerbini M, Musiani M, Roda A (2007): PNA-based probe for quantitative chemiluminescent in situ hybridisation imaging of cellular parvovirus BI9 replication kinetics. Analyst 132, 519-523. http://dx.doi.org/10.1039/b7() 1664f
17. Brass C, Elliott EM, Stevens DA (1982): Academy rash, a probable epidemic of erythema infectiosum (fifth disease). JAMA 248, 568-572. http://dx.doi.org/IO.IQ01/ jama. 1982.03330050050030
18. Brennand J, Cameron A (2008): Fetal anaemia: diagnosis and management. Best. Pract. Res. Clin. Obstet. Gynaecol. 22,15- 29. mip://dx.doi.org/10.1016/j.hpobgyn.2007.08.005
19. Poole BD, Kivovich V, Gilbert L, Naides SJ (2011): Parvovirus B19 Nonstructural Protein Induced Damage of Cellular DNA and Resultant Apoptosis. Int. J. Med. Sci. 8, 88-96. http://dx.doi.Org/IO.7l50/ijms.8.8S
20. Broliden K (2001): Parvovirus B19 infection in pediatric solidorgan and bone marrow transplantation. Pediatr. Transplant. 5,320-330. http://dx.doi.Org/IO.1034/j.l399-3046 ,2001.00035.x
21. Brown KE (2008): Human Parvoviruses. In Long SS, Pickering LK, Prober CG (Eds): Principles and Practice of Pediatric Infectious Diseases. 3rd ed. Philadelphia, PA: Churchill Livingstone Elsevier, pp. 1072-1076. http://dx.doi.org/10.1016/B978-0-7020-3468-8.50220-0
22. Brown KE, Young NS, Alving BM, Barbosa LH (2001): Parvovirus B19 implications for transfusion medicine.Summary of a workshop. Transfusion 41, 130-135. http://dx.doi.org/10.1046/j. 1537-2995.2001.41010130.x
23. Cavallo R, Merlino C, Re D, Bollero C, Bergallo M, Lembo D, Musso T, Leonardi G, Segoloni GP, Ponzi AN (2003): B19 virus infection in renal transplant recipients. J. Clin. Virol. 26, 361-368. http://dx.doi.org/10.1016/S1386- 6532(02)00104-X
24. Chapman MS, Rossmann MG (1993): Structure, sequence, and function correlations among parvoviruses. Virology 194, 491-508. http://dx.doi.org/10.IQ06/viro.l993.l288
25. Choi SH, Chang SP, Won JC, Lee JS, Chi HS, Yang WS, Park SK (2002): A case of persistent anemia in a renal transplant recipient: Association with parvovirus B19 infection. Scand. J. Infect. Dis. 34, 71-75. http://dx.doi.org/10.1080/003655402753395247
26. Chorba T, Coccia P, Holman RC (1986): The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J. Infect. Dis. 154, 383-393. http://dx.doi.org/10.1093/ infdis/154.3.383
27. Cohen BJ, Buckley MM (1988): The prevalence of antibody to human parvovirus B19 in England and Wales. J. Med. Microbiol. 25,151-153. http://dx.doi.org/10.1099/00222615-25-2-151
28. Cohen BJ, Mortimer PP, Pereira MS (1983): Diagnostic assays with monoclonal antibodies for the human serum parvovirus like virus (SPLV). J. Hyg. 91, 113-130. http://dx.doi.org/10.1017/S0022172400060095
29. Corcoran A, Doyle S (2004): Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J. Med. Microbiol. 53,459-475. http://dx.doi.org/10.IQ99/ jmm.0.05485-0
30. Cossart YE (1981): Parvovirus B19 finds a disease. Lancet 2,988- 989. http://dx.doi.org/IQ.I016/S0140-6736(81)91185-5
31. Cossart YE, Field AM, Cant B, Widdows D (1975): Parvovirus-like particles in human sera. Lancet 1, 72-73.
32. Cotmore SF, McKie VC, Anderson LJ (1986): Identification of the major structural and nonstructural proteins encoded by human parvovirus BI9 and mapping of their genes by procaryotic expression of isolated genomic fragments. J. Virol. 60, 548-557.
33. Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, Montagnier-Petrissans C, Guillevin L (2012): Intravenous Immunoglobulin Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection: A Retrospective Study of 10 Patients and Review of the Literature. Clin. Infect. Dis. 56, 968-977. http://dx.doi.org/10. IQ93/cid/cisl046
34. De Jong EP, Walther FJ, Kroes AC, Oepkes D (2011): Parvovirus B19 infection in pregnancy: new insights and management. Prenat. Diagn. 31, 419-25. http://dx.doi.org/l().1002/pd.27l4
35. Diaz F, Collazos J (2000): Hepatic dysfunction due to parvovirus B19 infection. J. Infect. Chemother. 6, 63-64. htlp.7/ dx.doi.org/l().1007/sl01560050052
36. Doerig C, Hirt B, Antonietti JP, Beard P (1990): Nonstructural protein of parvoviruses B19 and minute virus of mice controls transcription. J. Virol. 64, 387-396.
37. Doyle S (2011): The detection of parvoviruses. Methods Mol. Biol. 665, 213-231. http://dx.d0i.0rg/l0.1007/978-1- 60761-817-1 13
38. Duedu KO, Sagoe KWC, Ayeh-Kumi PF, Affrim RB, Adiku T (2013): The effects of co-infection with human parvovirus B19 and Plasmodium falciparum on type and degree of anaemia in Ghanaian children. Asian Pac. J. Trop. Biomed. 3, 129-139. http://dx.doi.org/10.1016/S2221 - 1691(13)60037-4
39. Egbuna O, Zand MS, Arbini A., Menegus M, Taylor J (2006): A cluster of parvovirus B19 infections in renal transplant recipients: A prospective case series and review of the literature. Am. J. Transplant. 6, 225-231. http://dx.doi.org/10.1111/i. 1600-6143.2005.01139.x
40. Eid AJ, Brown RA, Patel R, Razonable RR (2006): Parvovirus B19 infection after transplantation: A review of 98 cases. Clin. Infect. Dis. 43, 40-48. http://dx.doi.orjT/10.1086/504812
41. Enders M, Schalasta G, Baisch C (2006): Human parvovirus B19 infection during pregnancy value of modern molecular and serological diagnostics. J. Clin. Virol. 35, 400-406. http://dx.doi.Org/10.I016/i.icv.2005.ll.002
42. Ergaz Z, Ornoy A (2006): Parvovirus B19 in pregnancy. Reprod Toxicol. 21, 421-35. http://dx.doi.0rg/lO.lOl6/i.reprotox.2005.01.006
43. Eranssil R, Hokynar K, Hedman K (2001): T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirusb 19. J. Infect. Dis. 183,805-809. http://dx.doi.org/10.1086/318819
44. Fu Y, Ishii KK, Munakata Y, Saitoh T, Kaku M, Sasaki T (2002): Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J. Virol. 76, 5395-5403. http://dx.doi.org/10.1128/IV1.76.11.5395-5403.2002
45. Gallinella G, Bonvicini F, Filippone C (2004): Calibrated realtime PCR for evaluation of parvovirus B19 viral load. Clin. Chem. 50, 759-762. http://dx.doi.org/10.1373/ clinchem.2003.027292
46. Gallinella G, Young NS, Brown KE (1994): In situ hybridisation and in situ polymerase chain reaction detection of parvovirus B19 DNA within cells. J. Virol. Methods 50,67-74. http:// dx.doi.org/10.1016/0166-0934(94)90164-3
47. Gallinella G, Zerbini M, Musiani M, Venturoli S, Gentilomi G, Manaresi E (1997): Quantitation of parvovirus B19 DNA sequences by competitive PCR: differential hybridization of the amplicons and immunoenzymatic detection on microplate. Mol. Cell. Probes 11,127-133. http://dx.doi.org/10.1006/mcpr.1996.0095
48. Gallinella G, Zuffi E, Gentilomi G (2003): Relevance of B19 markers in serum samples for a diagnosis of parvovirus B19 correlated diseases. J. Med. Virol. 71, 135-139. http:// dx.doi.org/10.1002/imv.10452
49. Qeetha D, Zachary, JB, Baldado H M, Kronz JD Kraus ES (2000): Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: A case report and review of literature. Clin. Transplant. 14,586-591. http://dx.doi,org/10.1034/i.l399-0012.2000.140612.x
50. Gentilomi G, Zerbini M, Musiani M (1993): In situ detection of B19 DNA in bone marrow of immunodeficient patients using a digoxigenin-labelled probe. Mol. Cell. Probes 7,19-24. http://dx.doi.oi-g/10.1006/mcpr.1993.1003
51. Gigler A, Dorsch S, Hemauer A (1999): Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J. Virol. 73, 1974-1979.
52. Giorgio G (2013): Parvovirus B19 Achievements and Challenges: Review. ISRN Virol. 2013, 1-33.
53. Grabarczyk P, Kalinska A, Kara M (2011): Identification and characterization of acute infection with parvovirus B19 genotype 2 in immunocompromised patients in Poland. J. Med. Virol. 83, 142-149. http://dx.doi.org/10.1002/ jmv.21947
54. Gruber F, Falkner FG, Dorner F, Hammerle T (2001): Quantitation of viral DNA by real-time PCR applying duplex amplification, internal standardization, and two-color fluorescence detection. Appl. Environ. Microbiol. 67, 2837-2839. http://dx.doi.org/10.1128/AEM.67.6.2837-2839.2001
55. Guan W, Wong S, Zhi N, Qiu J (2009): The genome of human parvovirus B19 can replicate in nonpermissive cells with the help of adenovirus genes and produces infectious virus. J. Virol. 83, 9541-9553. http://dx.doi.org/10.H28/ 1VI.00702-09
56. Harbison CE, Chiorini JA, Parrish CR (2008): Ihe parvovirus capsid odyssey: from the cell surface to the nucleus. Trends Microbiol. 16, 208-214. http://dx.doi.Org/10.1016/j.tim.2008.01.012
57. Heegaard ED, Brown KE (2002): Human Parvovirus B19. Clin. Microbiol. Rev. 15, 485-505 http://dx.doi.org/10.1128/ CMR. 15.3.485-505.2002
58. Heegaard ED, Laub PB (2000): Parvovirus B19 transmitted by bone marrow. Br. I. Haematol. I l l, 659-661. http://dx.doi.org/10.1046/i. 1365-2141.2000.02407.x
59. Hokynar K, Soderlund-Venermo M, Pesonen M, Ranki A, Kiviluoto O, Partio EK, Hedman K (2002): A new parvovirus genotype persistent in human skin. Virology 302, 224-228. http://dx.doi.org/10.l006/viro.2002.1673
60. Hsu GJ, Tzang BS, Tsai CC, Chiu CC, Huang CY, Hsu T (2011): Effects of human parvovirus B19 on expression of defensins and Toll-like receptors. Chin. J. Physiol. 54, 367-376.
61. Isa A, Kasprowicz V, Norbeck O, Loughry A, Jeffery K., Broliden K, Klenerman P, Tolfvenstam T, Bowness P (2005): Prolonged activation of virus-specific CD8+T cells after acute B19 infection. PLoS Med. 2, e343. http://dx.doi.org/10.1371 /iournal.pmed.0020343
62. Isa A, Norbeck O, Hirbod T, Lundqvist A, Kasprowicz V, Bowness P, Klenerman P, Broliden K, Tolfvenstam T (2006): Aberrant cellular immune responses in humans infected persistently with parvovirus B19. J. Med. Virol. 78, 129-133. http://dx.doi.org/10.1002/imv.20514
63. Jordan JA (1996): Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am. J. Obstet. Gynecol. 174, 37-42. http://dx.doi.org/lO.1016/S0002- 9378(96)70370-8
64. Kahn JS, Kesebir D, Cotmore SF (2008): Seroepidemiology of human bocavirus defined using recombinant virus like particles. J. Infect. Dis. 198, 41-50. http://dx.doi.org/10.1086/588674
65. Kaikkonen L, Lankinen H, Harjunpaa I (1999): Acute phase specific heptapeptide epitope for diagnosis of parvovirus B19 infection. J. Clin. Microbiol. 37, 3952-3956.
66. Katragadda L, Shahid Z, Restrepo A, Muzaffar J, Alapat D, Anaissie E (2013): Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease. Transpl. Infect. Dis. 15, 354-60. http://dx.doi.org/10.11II Aid. 12067
67. Kaufmann B, Chipman PR, Kostyuchenko VA Modrow S, Rossmann MG (2008): Visualization of the externalized VP2 N termini of infectious human parvovirus B19. J. Virol. 82, 7306-7312. http://dx.doi.org/10.1128/IV 1.00512-08
68. Kaufmann B, Simpson AA, Rossmann MG (2004): The structure ofhuman parvovirus B19. Proc. Natl. Acad. Sci. USA 101, 11628-11633. http://dx.doi.org/10.1073/ pnas.0402992101
69. Kelly HA, Siebert D, Hammond R, Leydon J, Kiely P, Maskill W (2000): The age-specific prevalence ofhuman parvovirus immunity in Victoria, Australia, compared with other parts of the world. Epidemiol. Infect. 124,449-457. http://dx.doi.org/10.1017/S0950268899003817
70. Kerr J R (2000): Pathogenesis ofhuman parvovirus B19 in rheumatic disease. Ann. Rheum. Dis. 59, 672-683. http://dx.doi.org/10.1 L36/ard.59.9.672
71. Kerr JR, Cunniffe VS, Kelleher P, Coats AJ, Mattey DL (2004): Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: Negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. J. Med. Virol. 74, 147- 155 http://dx.doi.org/IO.IOQ2/imv.20158
72. Kerr JR, McCoy M, Burke B, Mattey DL, Pravica V, Hutchinson IV (2003): Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection. J. Clin. Pathol. 56, 725-727. http://dx.doi.org/10.1136/jcp.56.10.725
73. Kerr S, O'Keeffe V, Kilty C, Doyle S (1999): Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J. Med. Virol. 57, 179-185. http://dx.doi.org/IO. 1()02/(S1CI) 1096-9071- (199902)57:2<179::A1D-IMVI6>3.0.CO;2-T
74. Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP (2005): Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112, 1965-1970. http://dx.doi.oig/10.U61/ C1RCULATIONAHA.105.548156
75. Kurtzman GJ, Gascon P, Caras M, Cohen B, Young NS (1988): B19parvovirus replicates in circulating cells of acutely infected patients. Blood 71, 1448-1454.
76. Kurtzman GJ, Ozawa K., Cohen B, Hanson G, Oseas R, Young NS (1987): Chronic bone marrow failure due to persistent parvovirusinfection. N. Engl. J. Med. 317,287-294. http:// dx.doi.org/10.1056/NEIM198707303170506
77. Lamont RF, Sobel JD, Vaisbuch E (2011): Parvovirus B19 infection in human pregnancy. BJOG 118,175-186. http://dx.doi.org/10.1 Ul/i.l47l-0528.2010.02749.x
78. Lefrere JJ, Servant-Delmas A, Candotti D (2005): Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 106, 2890-2895. http:// dx.doi.org/10.ll.82/blood-2005-03-1053
79. Levy HC, Bowman VD, Govindasamy L, McKenna R, Nash K., Warrington K, Chen W, Muzyczka N, Yan X, Baker TS, Agbandje McKenna M (2009): Heparin binding induces conformational changes in adeno-associated virus serotype 2. J. Struct. Biol. 165, 146-156. http://dx.doi.org/10.1016/i.isb.2008.12.002
80. Liefeldt L, Buhl M, Schweickert B, Engelmann E, Sezer O, Laschinski P, Preuschof L, Neumayer HH (2002): Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapy. Nephrol. Dial. Transplant. 17, 1840-1842. http://dx.doi.org/10.1093/ndt/17.10.1840
81. Lindblom A, Isa A, Norbeck O, Wolf S, Johansson B, Broliden K, Tolfvenstam T (2005): Slow clearance of human parvovirus B19 viremia following acute infection. Clin. Infect. Dis. 41, 1201-1203. http://dx.doi.org/10.1086/444503
82. Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A (2008): Human parvovirus B19 infection and autoimmunity. Autoimmun. Rev. 8, 116-120. http://dx.doi.org/10.1016/i.aut rev.2008.07.005
83. Lunardi C, Tiso M, Borgato L (1998): Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur. J. Immunol. 28, 936-48. http://dx.doi.org/10.1002/(SICn 1521-4141- n99803)28:03<936::AID-IMMU936>3.0.CO:2-X
84. Luo W, Astell CR (1993): A novel protein encoded by small RNAs of parvovirus B19. Virology 195, 448-455. http://dx.doi.org/10.1006/vi ro. 1993.1395
85. Luzzi GA, Kurtz JB (1985): Human parvovirus arthropathy and rheumatoid factor (Letter). Lancet 1,1218. http://dx.doi.org/10.1016/S0140-6736(85)92899-5
86. Magro CM, Dawood MR, Crowson AN (2000): The cutaneous manifestations of human parvovirus B19 infection. Hum. Pathol. 31, 488-497. http://dx.doi.org/10.1053/ hp.200O.6714
87. Magro CM, Wusirika R, Frambach GE, Nuovo GJ, Ferri C, Ross P Jr (2006): Autoimmune-like pulmonary disease in association with parvovirus B19: A clinical, morphologic, and molecular study of 12 cases. Appl. Immunohistochem. Mol.Morphol. 14,208-216. http://dx.doi.org/10.1097/01.pai.0000160730.54062.6d
88. Manaresi E, Gallinella G, Venturoli S, Zerbini M, Musiani M (2004): Detection of parvovirus B19 IgG: choice of antigens and serological tests. J. Clin. Virol. 29, 51-53. http://dx.doi.org/IO. 10I6/S1386-6532(()3)0Q088-X
89. Manaresi E, Gallinella G, Zuffi E, Bonvicini F, Zerbini M, Musiani M (2002): Diagnosis and quantitative evaluation of parvovirus B19 infections by real-time PCR in the clinical laboratory. J. Med. Virol. 67, 275-281. http:// dx.doi.org/10.1002/imv.22I8
90. Mani B, Baltzer C, Valle N, Almendral J. M, Kempf C, Ros C (2006): Low pH-dependent endosomal processing of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal sequence (N-VP1), N-VP2 cleavage, and uncoating of the full-length genome. J. Virol. 80, 1015-1024. http://dx.doi.org/10.H28/ J VI.80.2.1015-1024.2006
91. Marchand S, Tchernia G, Hiesse C, Tertian G, Cartron J, Kriaa F, Boubenider S, Goupy C, Lecointe D, Charpentier B (1999): Human parvovirus B19 infection in organ transplant recipients. Clin. Transplant. 13,17-24. http://dx.doi.org/10.1034/i. 1399-0012.1999.t01-l-130l()3.x
92. Meryl W, Jeffrey BK (2007): Parvovirus B19 and the Kidney. Clin. J. Am. Soc. Nephrol. 2, S47-S56. http://dx.doi.org/10.2215/CJN.01060307
93. Modrow S, Dorsch S (2002): Antibody responses in parvovirus B19 infected patients. Pathol. Biol. 50, 326-331. http:// dx.doi.org/10.1016/S0369-8114(02100302-4
94. Moffatt S, Tanaka N, Tada K (1996): A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interIeukin-6 gene expression. J. Virol. 70, 8485-8491.
95. Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K (1998): Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J. Virol. 72, 3018-3028.
96. Molenaar-de Backer MW, Lukashov VV, van Binnendijk RS, Boot HJ, and Zaaijer HL (2012): Global co-existence of two evolutionary lineages of parvovirus B19 la, different in genome-wide synonymous positions. PLoS One 7, e43206. http://dx.doi.org/10.137l/iournaLoj> ne.0043206
97. Momoeda M, Wong S, Kawase N, Young S, Kajigaya S (1994): A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. J. Virol. 68, 8443-8446.
98. Morey AL, Porter HJ, Keeling JW, Fleming KA (1992): Nonisotopic in situ hybridisation and immunophenotyping of infected cells in the investigation of human fetal parvovirus infection. J. Clin. Pathol. 45, 673-678. http:// dx.doi.org/10.1136/jcp.45.8.673
99. Morey AL, Ferguson DJP, Fleming KA(1995): Combined immunocytochemistry and non-isotopic in situ hybridization for the ultrastructural investigation of human parvovirus B19 infection. Histochem. J. 27, 46-53. http://dx.doi.org/10.1007/BF00164171
100. Morita E, Nakashima A, Asao H, Sato H, Sugamura K (2003): Human parvovirus B19 nonstructural protein (NS 1) induces cell cycle arrest at G(l) phase. J. Virol. 77, 2915-2921. http://dxdoi.Org/10.ll28/JVI.77.5.2915-2921.2003
101. Mossong J, Hens N, Friederichs V (2008): Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiol. Infect. 136,10S9-1068. http://dx.doi.org/10.l017/ S0950268807009661
102. Moudgil A, Shidban H, Nast CC, Bagga A, Aswad S, Graham SL, Mendez R, Jordan SC (1997): Parvovirus B19 infectionrelated complications in renal transplant recipients: Treatment with intravenous immunoglobulin. Transplantation 64, 1847-1850. http://dx.d0i.0rg/l 0.1097/00007890- J99712270-00037
103. Munakata Y, Saito-Ito T, Kumura-Ishii K, Huang J, Kodera T, Ishii T, Hirabayashi Y, Koyanagi Y, Sasaki T (2005): Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106, 3449-3456. http://dx.doi.org/10.1182/blood-2005-02-0536
104. Murer L, Zacchello G, Bianchi D, Dall'Amico R, Montini G, Andreetta B, Perini M, Dossi EC, Zanon G, Zacchello F (2000): Thrombotic microangiopathy associated with parvovirus B19 infection after renal transplantation. J. Am. Soc. Nephrol. 11, 1132-1137.
105. Musiani M, Gallineiia G, Venturoli S, Zerbini M (2007): Competitive PCR ELISA protocols for the quantitative and the standardized detection of viral genomes. Nat. Protoc. 2, 2511-2519. http://dx.doi.org/10.1038/nprot.2007.312
106. Musiani M, Manaresi E, Gallineiia G, Cricca M, Zerbini M (2005): Recurrent erythema in patients with long-term parvovirus B19 infection. Clin. Infect. Dis. 40, el 17-ell9. http:// dx.doi.org/10.1086/430442
107. Mustafa MM, McClain KL (1996): Diverse hematologic effects of parvovirus B19 infection. Pediatr. Clin. North Am. 43 809-821. http://dx.doi.org/10.1016/S003 1 - 3955(05)70434-X
108. Nakazawa T, Tomosugi N, Sakamoto K, Asaka M, Yuri T, Ishikawa I, Kitagawa S (2000): Acute glomerulonephritis after human parvovirus B19 infection. Am. J. Kidney Dis. 35, E31. http://dx.doi.org/10.1016/S0272- 6386(00170070-9
109. Nguyen QT, Sifer C, Schneider V, Allaume X, Servant A, Bernaudin F, Auguste V, Garbarg-Chenon A (1999): Novel human erythrovirus associated with transient aplastic anemia. J. Clin. Microbiol. 37, 2483-2487.
110. Nigro G, Zerbini M, Krzysztofiak A, Gentilomi G, Porcaro MA, Mango T, Musiani M (1994): Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet 343, 1260-1261. http://dx.doi.org/10.1016/S0140- 6736(94)92154-7
111. Nikkari S, Roivainen A, Hannonen P, Mottonen T, Luukkainen R, Yli-JamaT,Toivanen P(1995): Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann. Rheum. Dis. 54, 597-600. http://dx.doi.Org/10.ll36/ard.54.7.597
112. Norbeck O, Isa A, Pohlmann C (2005): Sustained CD8+T-cell responses induced after acute parvovirus BI9 infection in humans: J. Virol. 79, 12117-12121. http://dx.doi.org/10.1128/JV1.79.18.12117-12121.2005
113. Onguru P, Dede F, Bodur H, Ayli D, Akinci E, Cevik MA, Kilic A (2006): Glomerulonephritis associating parvovirus B19 infection. Ren. Fail. 28, 85-88. http://dx.doi.01- g/10.1080/08860220500461302
114. Opaleye OO, Fagbami AH, Lalremruata A, Kun JF (2011): Prevalence and association of human parvovirus B19V with hepatitis B and C viruses in Nigeria. J. Med. Virol. 83, 710-716. http://dx.doi.org/10.1002/imv.22008
115. Ozawa K, Young N (1987): Characterization of capsid and non capsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J. Virol. 61, 2627-2630.
116. Ozawa K, Ayub J, Kajigaya S, Shimada T, Young N (1988): The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J. Virol. 62, 2884-2889.
117. Pamidi S, Friedman K., Kampalath B, Eshoa C, Hariharan S (2000): Human parvovirus B19 infection presenting as persistent anemia in renal transplant recipients. Transplantation 69, 2666-2669. http://dx.doi.org/10.1097/00007890- 200006270-00030
118. Parsyan A, Kerr S, Owusu-Ofori S, Elliott G, Allain JP (2006): Reactivity of genotype specific recombinant proteins of human erythrovirus B19 with plasmas from areas where genotype 1 or 3 is endemic. J. Clin. Microbiol. 44,1367-1375. http:// dx.doi.org/10.U28/ICM.44.4.1367-1375.2006
119. Pattison JR, Jones SE, Hodgson J, Davis LR, White JM, Stroud CE, Murtaza L (1981): Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1, 664-665. http://dx.doi.org/10.1016/SO140-6736(81)91579-8
120. Peterlana D, Puccetti A, Corrocher R, Lunardi C (2006): Serologic and molecular detection of human parvovirus B19 infection. Clin. Chim. Acta 372, 14-23. http://dx.doi.org/l().1016/j.cca.2006.04.018
121. Raab U, Beckenlehner K, Lowin T (2002): NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp 1 /Sp3. Virology 293,86-93. http://dx.cloi.org/10.1006/ viro.2001.128
122. Sabella C, Goldfarb J (1999): Parvovirus B19 infections. Am Fam Physician. 60,1455-1460.
123. Sackelton LA, Holmes EC (2006): Phylogenetic evidence for the rapid evolution of human B19 erythrovirus. J. Virol. 76, 9124.
124. Saikawa T, Anderson S, Momoeda M, Kajigaya S, Young NS (1993): Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J. Virol. 67, 3004-3009.
125. Salimans MMM, VandeRijke FM, Raap AK, van Elsacker-Niele AMW (1989): Detection of parvovirus B19 DNA in fetal tissues by in situ hybridisation and polymerase chain reaction. J. Clin. Pathol. 42, 25-530. http://dx.doi.org/ 10.1136/jcp,42.5.525
126. Salimi V, Gouya MM, Esteghamati AR, Safaie A, Heshmat R, Saadatmand Z, Mokhtari-Azad T (2008): Seroepidemiology of Human Parvovirus B19 in 5-25 Year Old Age People in Iran. Iran J. Public. Health 37,19-25.
127. Serjeant G R, Topley JM, Mason K, Serjeant BE, Pattison JR, Jones SE (1981): Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet 2,595-597. http://dx.doi.org/10.1016/S0140-6736(81192739-2
128. Serjeant GR, Serjeant BE, Thomas PW, Anderson MJ, Patou G, Pattison JR. (1993): Human parvovirus infection in homozygous sickle cell disease. Lancet 341, 1237-1240, hltp.7/dx.doi.org/10.1016/0140-6736(93)91145-C
129. Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, Garbarg-Chenon A (2002): Genetic diversity within human erythroviruses: Identification of three genotypes. J. Virol. 76, 9124-9134. http://dx.doi.org/10.1128/1VI.76.18.9124-9134.2002
130. Servey JT, Reamy BV, Hodge J (2007): Clinical presentations of parvovirus B19 infection. Am. Fam. Physician. 75, 373-376.
131. So K, Macquillan G, Garas G, Delriviere L, Mitchell A, Speers D, Mews C, Augustson B, de Boer WB, Baker D, Jeffrey GP (2007): Urgent liver transplantation for acute liver failure due to parvovirus B19 infection complicated by primary Epstein-Barr virus and cytomegalovirus infections and aplastic anaemia. Intern Med J. 37, 192-195. http:// dx.doi.orn/10.1111 /i. 1445-5994.2006.01293.x
132. Soderlund-Venermo M, Hokynar K., Nieminen J, Rautakorpi II, Hedman K. (2002): Persistence of human parvovirus B19 in human tissues. Pathol Biol. 50,307-316. http://dx.doi.org/10.1016/S0369-8114(02100307-3
133. Sol N, Le Junter L, Vassias I, Freyssinier JM, Thomas A, Frigent AF, Rudkin BB, Fichelson S, Morinet F (1999): Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J. Virol. 73, 8762-8770.
134. Sol N, Morinet F, Alizon M, Hazan U (1993): Trans-activation of the long terminal repeat of human immunodeficiency virus type 1 by the parvovirus B19 NS1 gene product. J. Gen. Virol. 74, 2011-2014. http://dx.doi.org/10.1099/0022-1317-74-9-2011
135. Takahashi M, Ito M, Sakamoto F, Shimizu N, Furukawa T, Takahashi M, Matsunaga Y (1995): Human parvovirus B19 infection: Immunohistochemical and electron microscopic studies of skin lesions. J. Cutan Pathol. 22, 168-172. http,7/dx.doi,ore/10,1111/i. 1600-0560.1995.lb() 1402.x
136. Takahashi T, Ozawa K, Takahashi K, Asano S, Takaku F (1990): Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 75, 603-610.
137. Taylor G, Drachenberg C, Faris-Young S (2001): Renal involvement of human parvovirus B19 in an immunocompetent host. Clin. Infect. Dis. 32, 167-169. http://dx.doi.org/10.1086/317556
138. Tolfvenstam T, Oxenius A, Price DA, Shacklett BL, Spiegel HM, Hedman K, Norbeck O, Levi M, Olsen K, Kantzanou M, Nixon DF, Broliden K, Klenerman P (2001): Direct ex vivo measurement of CD8 (+) T-lymphocyte responses to human parvovirus BI9. J. Virol. 75, 540-543. http:// dx.doi.org/10.1128/JVI.75.1.540-543.2001
139. von Poblotzki A, Gerdes C, Reischl U, Wolf H, Modrow S (1996): Lymphoproliterative responses after infection with human parvovirus B19. J. Virol. 70, 7327-7330.
140. Weigel-KelleyKA,YoderMC,SrivastavaA(2003):Alpha5betal integrin as a cellular coreceptor for human parvovirus B19: Requirement of functional activation of betal integrin for viral entry. Blood 102, 3927-3933. http:// dx.doi.org/10.1182/blood-2003-05-1522
141. White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA (1985): Human parvovirus arthropathy. Lancet 1,419- 421. http://dx.doi.orti/IO, 1016/S0140-6736(85)91145-6
142. Wierenga KJ, Pattison JR, Brink N, Griffiths M, Miller M, Shah DJ, Williams W, Serjeant BE, Serjeant GR (1995): Glomerulonephritis after human parvovirus infection in homozygous sickle-cell disease. Lancet 346, 475-476. http://dx.doi.oni/10.1016/SO140-6736(95)91324-6
143. Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, Caul O, Dieppe PA (1989): Clinical manifestations of human parvovirus B19 in adults. Arch. Intern. Med. 149, 1153-1156. http://dx.doi.org/10.1001/archinte.1989.00390050111022
144. Young NS, Brown KE (2004): "Parvovirus B19". N. Engl. J. Med. 350, 586-597. http://dx.doi.org/IO.1056/NEJMra030840
145. Zerbini M, Gibellini D. Musiani M, Venturoli S, Gallinella G, Gentilomi G (1995): Automated detection of digoxigenin labelled B19 parvovirus amplicons by a capture hybridization assay. J. Virol. Methods 55, 1-9. http://dx.doi.org/10.1016/0166-0934(9510003 8-V
146. Zhi N, Mills IP, Lu J, Wong S, Filippone C, Brown KE (2006): Molecular and functional analyses of a human parvovirus B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity. J. Virol. 80, 5941-5950. http:// dx.doi.org/IO.1128/JVI.02430-05
147. Zhou S, Ou R, Huang L, Price GE, Moskophidis D (2004): Differential tissue-specific regulation of antiviral CD8+ T-cell immune responses during chronic viral infection. J. Virol, 78,3578-3600. http://dx.doi.om/10.1128/JV1.78.7.3578- 3600.2004
148. Zolnourian ZR, Curran MD, Rima BK, Coyle PV, O'Neill HJ, Middleton D(2000): Parvovirus B19 in kidney transplant patients. Transplantation 69, 2198-2202. http://dx.doi.org/10.1097/00007890-200005270-00043